CVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, plans to release its second quarter 2022 financial results on July 28, 2022, after market close. A conference call to discuss these results will take place at 5:30 p.m. Eastern Time the same day. The event will be available via webcast and telephone registration is recommended. CVRx's flagship product, Barostim, is an FDA-approved device aimed at alleviating heart failure symptoms by enhancing the autonomic nervous system's balance.

MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2022 financial and operating results after market close on Thursday, July 28th, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/8r349o6o. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:

Erich Sandoval
Finn Partners
212-867-1762
erich.sandoval@finnpartners.com

FAQ

When will CVRx release its second quarter 2022 financial results?

CVRx plans to release its second quarter 2022 financial results on July 28, 2022, after market close.

What time is the CVRx conference call scheduled for?

The conference call for CVRx's second quarter 2022 results is scheduled for 5:30 p.m. Eastern Time on July 28, 2022.

How can I listen to the CVRx conference call?

You can listen to the CVRx conference call via a live webcast or by registering for a telephone call.

What is Barostim and how does it work?

Barostim is an implantable device developed by CVRx that uses neuromodulation to improve symptoms of heart failure by delivering electrical pulses to baroreceptors, helping to restore balance in the autonomic nervous system.

Has Barostim received any regulatory approvals?

Yes, Barostim has received FDA Breakthrough Device designation and is FDA-approved for heart failure patients in the U.S., as well as CE Mark for heart failure and resistant hypertension in Europe.